Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Relmada Therapeutics Inc | RLMD | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 3.86 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.86 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 2.3601 - 7.2225 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 3.86 | USD |
Relmada Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 116.18M | 30.10M | - | 0 | -98.79M | -3.28 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Relmada Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RLMD Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.65 | 4.72 | 3.70 | 3.96 | 135,029 | -0.79 | -16.99% |
| 1 Month | 4.71 | 5.09 | 3.70 | 4.47 | 120,479 | -0.85 | -18.05% |
| 3 Months | 4.36 | 7.2225 | 3.70 | 5.19 | 217,800 | -0.50 | -11.47% |
| 6 Months | 3.04 | 7.2225 | 2.415 | 4.05 | 234,775 | 0.82 | 26.97% |
| 1 Year | 2.51 | 7.2225 | 2.3601 | 3.55 | 203,530 | 1.35 | 53.78% |
| 3 Years | 37.01 | 40.00 | 1.81 | 12.23 | 320,921 | -33.15 | -89.57% |
| 5 Years | 10.85 | 54.00 | 1.81 | 16.82 | 255,893 | -6.99 | -64.42% |
Relmada Therapeutics Description
| Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications. |
